MOTS‑c (Mitochondrial Open Reading Frame of the Twelve S rRNA‑c) by Hilma Biocare: metabolism, endurance & anti‑aging
MOTS‑c is a 16‑amino‑acid mitochondrial signalling peptide that re‑programmes cells toward fat burning, improves insulin sensitivity, boosts endurance and helps slow the ageing process. Naturally rising after exercise, it acts as an “exercise mimetic” and is widely used to optimise metabolic health.
Key actions
- AMPK activation: Enhances cellular energy sensing, reduces insulin resistance and promotes lipolysis.
- Metabolic stress adaptation: Translocates to the nucleus, modulating gene expression for better stress resilience.
- Anti‑aging & inflammation: Protects mitochondria, lowers oxidative stress, and curbs chronic inflammation.
- Performance & recovery: Increases endurance, improves muscle adaptation and speeds post‑exercise healing.
- Cardiovascular support: Safeguards cardiomyocytes and improves endothelial function.
Dosage & administration
- Form: Lyophilised peptide for sub‑cutaneous injection (abdomen or thigh).
- Initial dose: 2.5 mg per injection.
- Typical escalation:
- Maintenance: 5 mg per injection
- Intensive therapy: up to 10 mg per injection
- Frequency: 1‑2 times per week (physician‑directed). Daily dosing is not advised; higher intermittent doses yield longer‑lasting transcriptional changes (3‑7 days).
- Course length: Initial 4‑6 weeks, followed by a maintenance phase up to 10 weeks with weekly administration.
- Synergy: Can be combined with BPC‑157, GLP‑1 agonists or other peptides for enhanced metabolic effect.
Contra‑indications
- Pregnancy or breastfeeding
- Age under 21
- Active tumours, acute infections or autoimmune disease
- Avoid alcohol and concurrent antibiotic therapy
Side effects
- Generally safe; rare reports of mild tachycardia or insomnia
- Minimal injection‑site irritation
- Potential hypoglycaemia when combined with hypoglycaemic drugs – monitor blood glucose.
Compatibility with other products
MOTS‑c works well alongside other performance‑enhancing peptides (e.g., BPC‑157) and metabolic agents (GLP‑1 agonists). Always consult a physician for personalized stacking.
Conclusion
MOTS‑c by Hilma Biocare provides a scientifically supported way to mimic exercise‑induced metabolic benefits, improve insulin sensitivity, increase endurance and support anti‑ageing pathways. Its intermittent dosing schedule and low side‑effect profile make it a practical addition to advanced health‑optimisation protocols.